367 related articles for article (PubMed ID: 34948400)
21. Comparative analysis of dynamic transcriptomes reveals specific COVID-19 features and pathogenesis of immunocompromised populations.
Yang X; Zhu J; Wang Q; Tang B; Shen Y; Wang B; Ji L; Liu H; Wuchty S; Zhang Z; Dong Y; Liang Z
mSystems; 2024 Jun; 9(6):e0138523. PubMed ID: 38752789
[TBL] [Abstract][Full Text] [Related]
22. Alzheimer's disease in elderly COVID-19 patients: potential mechanisms and preventive measures.
Wang H; Lu J; Zhao X; Qin R; Song K; Xu Y; Zhang J; Chen Y
Neurol Sci; 2021 Dec; 42(12):4913-4920. PubMed ID: 34550494
[TBL] [Abstract][Full Text] [Related]
23. The Neuropathological Impacts of COVID-19: Challenges and Alternative Treatment Options for Alzheimer's Like Brain Changes on Severely SARS-CoV-2 Infected Patients.
Rahman MR; Akter R; Neelotpol S; Mayesha II; Afrose A
Am J Alzheimers Dis Other Demen; 2023; 38():15333175231214974. PubMed ID: 37972355
[TBL] [Abstract][Full Text] [Related]
24. Calcium Channel Blockers: A Possible Potential Therapeutic Strategy for the Treatment of Alzheimer's Dementia Patients with SARS-CoV-2 Infection.
Danta CC
ACS Chem Neurosci; 2020 Aug; 11(15):2145-2148. PubMed ID: 32662982
[TBL] [Abstract][Full Text] [Related]
25. Genetic Exchange of Lung-Derived Exosome to Brain Causing Neuronal Changes on COVID-19 Infection.
Ahmed SSSJ; Paramasivam P; Kamath M; Sharma A; Rome S; Murugesan R
Mol Neurobiol; 2021 Oct; 58(10):5356-5368. PubMed ID: 34312772
[TBL] [Abstract][Full Text] [Related]
26. COVID-19: Oxidative Preconditioning as a Potential Therapeutic Approach.
Akki R; Fath N; Mohti H
ACS Chem Neurosci; 2020 Nov; 11(22):3732-3740. PubMed ID: 33147964
[TBL] [Abstract][Full Text] [Related]
27. Whole-transcriptome sequencing data reveals a disparate cognitive and immune signature in COVID-19 patients with and without dementia.
Yang J; Song H; Hao X
J Med Virol; 2023 Jan; 95(1):e28177. PubMed ID: 36168207
[TBL] [Abstract][Full Text] [Related]
28. Molecular cross-talk between long COVID-19 and Alzheimer's disease.
Pszczołowska M; Walczak K; Misków W; Antosz K; Batko J; Karska J; Leszek J
Geroscience; 2024 Jun; 46(3):2885-2899. PubMed ID: 38393535
[TBL] [Abstract][Full Text] [Related]
29. The key role of the level of ACE2 gene expression in SARS-CoV-2 infection.
Lecarpentier Y; Vallée A
Aging (Albany NY); 2021 Jun; 13(11):14552-14556. PubMed ID: 34115612
[TBL] [Abstract][Full Text] [Related]
30. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
31. Glycogen synthase kinase-3: A putative target to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
Rana AK; Rahmatkar SN; Kumar A; Singh D
Cytokine Growth Factor Rev; 2021 Apr; 58():92-101. PubMed ID: 32948440
[TBL] [Abstract][Full Text] [Related]
32. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
33. COVID-19 Case Fatality and Alzheimer's Disease.
Zhang Q; Schultz JL; Aldridge GM; Simmering JE; Kim Y; Ogilvie AC; Narayanan NS
J Alzheimers Dis; 2021; 84(4):1447-1452. PubMed ID: 34690147
[TBL] [Abstract][Full Text] [Related]
34. Putative mechanism of neurological damage in COVID-19 infection.
Bandala C; Cortes-Altamirano JL; Reyes-Long S; Lara-Padilla E; Ilizaliturri-Flores I; Alfaro-Rodríguez A
Acta Neurobiol Exp (Wars); 2021; 81(1):69-79. PubMed ID: 33949163
[TBL] [Abstract][Full Text] [Related]
35. Alzheimer's-like signaling in brains of COVID-19 patients.
Reiken S; Sittenfeld L; Dridi H; Liu Y; Liu X; Marks AR
Alzheimers Dement; 2022 May; 18(5):955-965. PubMed ID: 35112786
[TBL] [Abstract][Full Text] [Related]
36. COVID-19 and Alzheimer's Disease: A Literature Review.
Hardan L; Filtchev D; Kassem R; Bourgi R; Lukomska-Szymanska M; Tarhini H; Salloum-Yared F; Mancino D; Kharouf N; Haikel Y
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833377
[TBL] [Abstract][Full Text] [Related]
37. The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning.
de Erausquin GA; Snyder H; Carrillo M; Hosseini AA; Brugha TS; Seshadri S;
Alzheimers Dement; 2021 Jun; 17(6):1056-1065. PubMed ID: 33399270
[TBL] [Abstract][Full Text] [Related]
38. Environmental Nanoparticles, SARS-CoV-2 Brain Involvement, and Potential Acceleration of Alzheimer's and Parkinson's Diseases in Young Urbanites Exposed to Air Pollution.
Calderón-Garcidueñas L; Torres-Jardón R; Franco-Lira M; Kulesza R; González-Maciel A; Reynoso-Robles R; Brito-Aguilar R; García-Arreola B; Revueltas-Ficachi P; Barrera-Velázquez JA; García-Alonso G; García-Rojas E; Mukherjee PS; Delgado-Chávez R
J Alzheimers Dis; 2020; 78(2):479-503. PubMed ID: 32955466
[TBL] [Abstract][Full Text] [Related]
39. COVID-19: a conundrum to decipher.
Deshmukh V; Tripathi SC; Pandey A; Deshmukh V; Vykoukal J; Patil A; Sontakke B
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5830-5841. PubMed ID: 32495923
[TBL] [Abstract][Full Text] [Related]
40. The interference between SARS-COV-2 and Alzheimer's disease: Potential immunological and neurobiological crosstalk from a kinase perspective reveals a delayed pandemic.
Mansour HM
Ageing Res Rev; 2024 Feb; 94():102195. PubMed ID: 38244862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
